Business Context and Reporting Period
This Form 8-K, dated February 18, 2021, reports that HighCape Capital Acquisition Corp. (HighCape) has entered into a definitive Business Combination Agreement with Quantum-SI Incorporated (Quantum-SI). Upon consummation, HighCape will be renamed Quantum-SI Incorporated ("New Quantum-SI"), and Quantum-SI will become a wholly-owned subsidiary. The transaction is expected to close in the second quarter of 2021, subject to stockholder approvals and other customary conditions.
Key Financial Metrics and Transaction Terms
- Transaction Valuation: The implied equity value is based on an exchange ratio calculation starting with a base of $810,000,000, adjusted for Quantum-SI's net cash position (cash minus debt) and certain transaction expenses.
- PIPE Financing: HighCape has secured commitments from institutional and accredited investors to purchase 42,500,000 shares of Class A common stock at $10.00 per share, generating aggregate gross proceeds of $425,000,000.
- Minimum Cash Condition: A closing condition requires that the aggregate cash proceeds available from HighCape's trust account (post-redemptions) plus PIPE proceeds equal no less than $160,000,000.
- Net Tangible Assets: Post-transaction, the combined company must have at least $5,000,001 of net tangible assets to satisfy Nasdaq listing requirements.
- Capital Structure: New Quantum-SI will adopt a dual-class structure. Class A stock carries one vote per share, while Class B stock (held by founder Dr. Jonathan M. Rothberg and permitted transferees) carries 20 votes per share. Class B shares have a "sunset" provision if beneficial ownership falls below 20%.
Material Changes and Consideration
Quantum-SI equityholders will receive shares of New Quantum-SI Class A common stock (or Class B for Series A preferred holders) based on the Exchange Ratio. Existing HighCape Class B common stock will convert one-for-one into New Quantum-SI Class A common stock. HighCape Class A common stock will remain outstanding. The filing does not provide specific historical revenue, profit, or cash flow metrics for either entity, as this is a transaction announcement rather than a periodic financial report.
Guidance, Risks, and Contingencies
- Closing Conditions: The transaction is contingent upon stockholder approvals from both HighCape and Quantum-SI, expiration of the HSR Act waiting period, Nasdaq listing approval, and the satisfaction of the minimum cash requirement.
- Termination Rights: Either party may terminate the agreement if the transaction is not consummated by August 17, 2021, or if regulatory approvals are denied, among other customary conditions.
- Risk Factors: Significant risks include the failure to meet closing conditions, disruption of operations, inability to obtain regulatory approval for Quantum-SI's products, competition, and the impact of the COVID-19 pandemic.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations regarding future performance and the timing of the combination.
Investor Verification Checklist
- Verify the final Exchange Ratio and pro forma share count once Quantum-SI's net cash and debt positions are finalized.
- Monitor the level of redemptions by HighCape public stockholders to ensure the $160,000,000 minimum cash condition is met.
- Review the upcoming Form S-4 Registration Statement for detailed financial data, risk factors, and the definitive proxy statement.
- Confirm the status of regulatory approvals, specifically the Hart-Scott-Rodino (HSR) waiting period and Nasdaq listing approval.
- Assess the voting power implications of the dual-class structure, specifically the 20-vote Class B shares held by Dr. Rothberg.